Organic compounds -- part of the class 532-570 series – Organic compounds – Phosphorus acids or salts thereof
Reexamination Certificate
1999-12-08
2004-09-21
Vollano, Jean F. (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Phosphorus acids or salts thereof
Reexamination Certificate
active
06794536
ABSTRACT:
BACKGROUND OF THE INVENTION
Disodium 3-amino-1-hydroxypropane-1,1-diphosphonate or “disodium pamidronate” has the formula:
It is commercially available as the lyophilized pentahydrate, under the name AREDIA® from Novartis Pharmaceuticals Corp., and is used to inhibit bone resorption, i.e., to treat moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. The preparation of the crystalline pentahydrate from pamidronic acid is disclosed by Stahl et al. in U.S. Pat. Nos. 4,711,880 and 4,639,338. This material is prepared by partially neutralizing a heated slurry of pamidronic acid with aqueous sodium hydroxide (NaOH) to pH 7-7.5 and then initiating crystallization at ≧50° C. The mixture is slowly cooled to 0-5° C. and the disodium pamidronate is collected by filtration. This product is described as having “excellent crystallinity” and as being “completely stable to storage under approximately normal ambient conditions.” It comprises about 24.1-25% water.
The crystalline product (“Modification E”) is contrasted with an amorphous product disclosed to be prepared by the general process of Jary et al. (U.S. Pat. No. 4,304,734). In Comparison Example 1 of the '338 patent, pamidronic acid is neutralized to pH 7.4 with aqueous NaOH and the reaction mixture is concentrated to dryness under reduced pressure at 60-70° C. and then dried at 20 mbar to constant weight. However, the amorphous product that is obtained is described as deliquescent in air, contains 12.9% of retained water and, as taught in the '338 patent, will convert to the pentahydrate. Stahl et al. also teach the interconversion of other crystalline forms of disodium pamidronate depending upon humidity and amount of water present, which demonstrates the difficulty in utilizing preformed disodium salts of pamidronic acid for further processing into sterile pharmaceutical dosage forms.
Thus, a need exists for a simple method to prepare disodium pamidronate and dosage forms thereof that are stable to storage and suitable for reconstitution and/or intravenous infusion/injection.
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical unit dosage form comprising an aqueous solution of disodium pamidronate enclosed in a suitable container, such as an ampule or vial, under an inert atmosphere. Preferably the container is designed for “single use”. Preferably, the container is formed of a material that does not contain calcium in a form that can be sequestered by the dissolved disodium pamidronate.
The present invention also provides a method for the preparation of amorphous, essentially anhydrous (≦1-2 wt-% water) disodium pamidronate (the “product”). This solid product can be stored under nitrogen at otherwise ambient conditions, and readily reconstituted with sterile water or physiological salt solutions for injection or infusion into a patient in need of treatment therewith.
The present method also comprises a method to make an aqueous solution of disodium pamidronate by addition of aqueous sodium hydroxide to a stirred slurry of pamidronic acid in an about 2:1 molar ratio of NaOH to acid, optionally comprising excess mannitol, to yield a clear solution of pH 6.5±0.1. Aqueous phosphoric acid is added as needed if the pH following NaOH addition is too high. A small amount of aqueous NaOH can be added if the pH is too low. Preferably, 1 N aqueous NaOH is used.
The solution is frozen and lyophilized under reduced pressure to yield amorphous, essentially anhydrous disodium pamidronate. The product is stable when stored under dry nitrogen at otherwise ambient conditions. Preferably, the about pH 6.5 solution is filtered and aliquots are introduced into suitable container(s), then frozen (−25 to −40° C.), lyophilized (10-25 mbar, 20-40° C.) in situ, and the containers sealed under positive nitrogen pressure to yield a plurality of unit dosage forms of solid disodium pamidronate, optionally in admixture with mannitol.
For example, vials containing 30 mg, 60 mg and 90 mg of sterile lyophilized disodium pamidronate, each optionally containing 470 mg, 400 mg, and 375 mg of mannitol can readily be prepared and utilized as disclosed in
Physician's Desk Reference
(52d ed., 1988) at pages 1824-1828.
The present invention further provides an improved method for the preparation of aqueous solutions and dosage forms of disodium pamidronate of defined composition, using pamidronic acid as a starting compound and titrating an aqueous pamidronic acid slurry having a concentration of about 0.1 to 0.5 M, preferably about 0.130 to about 0.135 M, to visual clarity at a pH of approximately 6.5 using aqueous sodium hydroxide (NaOH) or other suitable base to yield an aqueous solution of disodium pamidronate. Preferably, an about 2:1 molar ratio of NaOH or other metal hydroxide to pamidronic acid is used. Mannitol is an optional component of the slurry, preferably present in a molar excess to pamidronate as in the solutions described above, prior to lyophilization. Alternately, the solution is titrated to clarity using aqueous sodium hydroxide and the final pH adjusted to approximately 6.5±0.1 using phosphoric acid as needed. The clear aqueous solution of disodium pamidronate is then filtered and packaged as unit dosage forms comprising aliquots of the filtered solution.
This aspect of the present invention entirely eliminates the generation and isolation of various metastable, hydrated, crystalline and/or amorphous physical forms of disodium pamidronate (each of which can interchange with the other, depending upon the circumstance of available moisture or temperature in the substance environment). The present invention affords stable pamidronate compositions which can be stored at temperatures of, for example, 0° C. or less (frozen), about 2 to about 8° C. (refrigerated), or about 20 to about 30° C. (room temperature). The compositions can be used to prepare dosage forms suitable for therapeutic oral, rectal, transdermal, intranasal, or intravenous administration.
As used herein, the term “about” incorporates inherent variability of the parameter referenced, due to measurement techniques known to the art, i.e., pH, or water content (loss on drying).
REFERENCES:
patent: 3962432 (1976-06-01), Schmidt-Dünker
patent: 4142916 (1979-03-01), Ogasa et al.
patent: 4304734 (1981-12-01), Jary et al.
patent: 4327039 (1982-04-01), Blum et al.
patent: 4336243 (1982-06-01), Sanvordeker et al.
patent: 4439194 (1984-03-01), Harwood et al.
patent: 4513891 (1985-04-01), Hain et al.
patent: 4639338 (1987-01-01), Stahl et al.
patent: 4680416 (1987-07-01), Hokanson et al.
patent: 4711880 (1987-12-01), Stahl et al.
patent: 4797388 (1989-01-01), Francis
patent: 4814326 (1989-03-01), Rosini et al.
patent: 4816259 (1989-03-01), Matthews et al.
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 5096717 (1992-03-01), Wirth et al.
patent: 5139786 (1992-08-01), Ferrini et al.
patent: 5159108 (1992-10-01), Kieczykowski
patent: 5296475 (1994-03-01), Flesch et al.
patent: 5344825 (1994-09-01), Khanna et al.
patent: 5366965 (1994-11-01), Strein
patent: 5403829 (1995-04-01), Lehtinen et al.
patent: 5431920 (1995-07-01), Bechard
patent: 5449819 (1995-09-01), Venkataramani et al.
patent: 5569466 (1996-10-01), Tanner et al.
patent: 5650165 (1997-07-01), Akemi et al.
patent: 5780055 (1998-07-01), Habib et al.
patent: 5785985 (1998-07-01), Czech et al.
patent: 5888550 (1999-03-01), Cook et al.
patent: 5932240 (1999-08-01), D'Angelo et al.
patent: 6057306 (2000-05-01), Wilson et al.
patent: 1144806 (1997-03-01), None
patent: 19820974 (1998-05-01), None
patent: 0177443 (1984-08-01), None
patent: 0600834 (1992-11-01), None
patent: WO-96/05842 (1996-02-01), None
Journal of Chromatography A by Quitasol et al 671 pp 273-279, Sep. 1994.*
Merriam Webster's Collegiate Dictionary 10th edition, Editor Fredrick Mish, 1993.*
Physicians' Desk Reference (Handbook) editor R Arky edition 52 publisher Medical Economics Company Inc st Montvale New Jersey pp 1823-1828, Nov. 1997.*
CA
Aesqen, Inc.
Schwegman Lundberg Woessner & Kluth P.A.
Vollano Jean F.
LandOfFree
Method for preparation of disodium pamidronate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparation of disodium pamidronate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparation of disodium pamidronate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3215701